Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.

Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Controlled release systems release at least one pluribioactive antifungal drug exhibiting at least one additional bioactivity from the group consisting of spermiostatic, antineoplastic, antibacterial, antirestenotic and antiviral activities. The drug release system is designed for use as a spermiostatic contraceptive, intravaginal ringed-mesh which may also exhibit antiviral activity, an in situ-forming implant for treating different forms of cancer and topical film for treating or preventing bacterial and fungal infections.

Abstract: Self-setting, absorbable bioactive polycyanoacrylate-based composites include at least one inorganic phosphate salt or a combination of at least one inorganic phosphate salt and calcium silicate in a cyanoacrylate matrix. The composites can be reinforced with single- or multicomponent absorbable, warp-knitted mesh, thus producing a broad range of absorbable, bioactive biomaterials suitable for use not only as preferred absorbable alternatives to the commercial non-absorbable polymethyl methacrylate bone cements, but also for repairing or replacing cranial and maxillofacial bone defects and other complex defects through guided bone regeneration.

Abstract: Bioactive hydroforming luminal liner compositions are formed of an absorbable crystalline amphiphilic polyether-ester-urethane dissolved in a liquid derivative of a polyether glycol that undergoes transformation into a tissue-adhering, resilient interior cover or liner for the controlled release of its bioactive payload at clinically compromised conduits in humans as in the case of bacteria- and yeast-infected vaginal canals, esophagi, and arteries following angioplasty.

Abstract: Self-setting, absorbable bioactive polycyanoacrylate-based composites include at least one inorganic phosphate salt or a combination of at least one inorganic phosphate salt and calcium silicate in a cyanoacrylate matrix. The composites can be reinforced with single- or multicomponent absorbable, warp-knitted mesh, thus producing a broad range of absorbable, bioactive biomaterials suitable for use not only as preferred absorbable alternatives to the commercial non-absorbable polymethyl methacrylate bone cements, but also for repairing or replacing cranial and maxillofacial bone defects and other complex defects through guided bone regeneration.